Sweden
# |
Name |
Gross Profit |
Reported Date | Stock Price |
Change |
Price (30 days) | Country |
---|---|---|---|---|---|---|---|
1 |
USD 51.95 M
|
Dec. 31, 2023 | USD 17.87 | 3.09% |
|
Sweden |
|
2 |
USD 7.05 M
|
Dec. 31, 2023 | USD 2.74 | 1.67% |
|
Sweden |
|
3 |
USD 7.00 M
|
Dec. 31, 2023 | USD 2.91 | -2.20% |
|
Sweden |
|
4 |
USD 2.81 M
|
Dec. 31, 2023 | USD 0.71 | -2.02% |
|
Sweden |
|
5 |
USD 2.80 M
|
Dec. 31, 2023 | USD 0.84 | -0.17% |
|
Sweden |
|
6 |
USD 1.11 M
|
Dec. 31, 2023 | USD 0.23 | 11.53% |
|
Sweden |
|
7 |
USD 295.80 K
|
Dec. 31, 2023 | USD 0.28 | -7.61% |
|
Sweden |
|
8 |
USD 259.64 K
|
Dec. 31, 2023 | USD 0.11 | 1.51% |
|
Sweden |
|
9 |
USD 144.40 K
|
Dec. 31, 2023 | USD 0.39 | 2.53% |
|
Sweden |
|
10 |
USD 102.15 K
|
Dec. 31, 2023 | USD 0.10 | 0.68% |
|
Sweden |
|
11 |
USD 5.23 K
|
Dec. 31, 2023 | USD 1.17 | -3.73% |
|
Sweden |
|
12 |
USD 296.10
|
Dec. 31, 2023 | USD 0.45 | 23.08% |
|
Sweden |
|
13 |
USD -346.90 K
|
Aug. 31, 2024 | USD 1.61 | 0.34% |
|
Sweden |
|
14 |
USD -1.79 M
|
Dec. 31, 2023 | USD 0.80 | 0.68% |
|
Sweden |
|
15 |
USD -2.10 M
|
Dec. 31, 2023 | USD 0.21 | 0.68% |
|
Sweden |
|
16 |
USD -3.40 M
|
Dec. 31, 2023 | USD 0.20 | 1.12% |
|
Sweden |
|
17 |
USD -4.24 M
|
Aug. 31, 2024 | USD 0.22 | -6.29% |
|
Sweden |
|
18 |
USD -12.11 M
|
Dec. 31, 2023 | USD 0.90 | 9.88% |
|
Sweden |
The Clinical Trials company in Sweden with the highest Gross Profit is BioArctic AB (publ) (Stockholm Stock Exchange: BIOA-B.ST) at USD 51.95 M.
The Clinical Trials company in Sweden with the lowest Gross Profit is IRLAB Therapeutics AB (publ) (Stockholm Stock Exchange: IRLAB-A.ST) at USD -12.11 M.
The top 10 Clinical Trials companies in Sweden by Gross Profit are BioArctic AB (publ), BioInvent International AB (publ), Hansa Biopharma AB (publ), Mendus AB (publ), Corline Biomedical AB, Elicera Therapeutics AB (publ), Clinical Laserthermia Systems AB (publ), Aptahem AB (publ), Pila Pharma AB (publ) and Kancera AB (publ).
The bottom 10 Clinical Trials companies in Sweden by Gross Profit are IRLAB Therapeutics AB (publ), NextCell Pharma AB, Isofol Medical AB (publ), CombiGene AB (publ), Prostatype Genomics AB (publ), Diamyd Medical AB (publ), OncoZenge AB (publ), Lipum AB (publ), Kancera AB (publ) and Pila Pharma AB (publ).